JPRN-UMIN000009734招募中2 期
Feasibility study of combination therapy with S-1 plus irinotecan in patients with EGFR positive KRAS mutation type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine, bevacizumab - Feasibility study of combination therapy with S-1 plus irinotecan in patients with EGFR positive KRAS mutation type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine, bevacizumab
3rd department of surgery Tokyo Medical University0 个研究点目标入组 25 人开始时间: 2013年1月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) With contraindicate S-1 2) Patients under treatment with flucytosine,phenytoin,warfarin potassium. 3) Severe bone marrow suppression 4) Active infection and inflammation 5)Comorbidity or history of interstitial lung disease or pulmonary fibrosis 6) Watery stools or diarrhea 7) Severe complications 8)Simultaneous or metachronous double cancers 9)Pregnant or lactating women or women of childbearing potential 10) Other patients who are unfit for the study as determined by the attending physician
研究者
相似试验
已完成
2 期
Feasibility study of S-1 as additional therapy after neo-adjuvant or adjuvant chemotherapy for triple negative breast cancer(SBCCSG-14).JPRN-UMIN000001414Saitama Breast Cancer Clinical Study Group(SBCCSG)60
已完成
2 期
Phase II study of combination therapy with S-1 plus cetuximab in patients with EGFR positive KRAS wild type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine(KSCC0901).Colorectal cancerJPRN-UMIN000002475Kyushu Study group of Clinical Cancer39
已完成
不适用
A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild typeJPRN-UMIN000005218Fukuoka Tumor Research(FUTURE)
招募中
1 期
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancerRefractory esophageal cancerJPRN-UMIN000007961Kyoto Prefectural University of Medicine18
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40